Skip to Content

ULTRA Hybrid FVRCP

This page contains information on ULTRA Hybrid FVRCP for veterinary use.
The information provided typically includes the following:
  • ULTRA Hybrid FVRCP Indications
  • Warnings and cautions for ULTRA Hybrid FVRCP
  • Direction and dosage information for ULTRA Hybrid FVRCP

ULTRA Hybrid FVRCP

This treatment applies to the following species:
Company: Elanco US

Feline Rhinotracheitis-Calici-Panleukopenia Vaccine

Modified Live & Killed Virus

For use in animals only

This product has been shown to be effective for vaccination of healthy cats 8 weeks of age or older against feline rhinotracheitis, calici and panleukopenia viruses. The duration of immunity for this product has not been determined. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

This vaccine contains two feline calicivirus strains and has been shown to induce a cross-neutralizing antibody response against multiple FCV isolates obtained from diverse locales across the United States.

Directions For Use

General directions: Aseptically rehydrate this product with the accompanying sterile diluent. Inject one 0.5 mL dose subcutaneously using aseptic technique. Do not vaccinate pregnant queens.

Primary vaccination: Healthy cats should receive two doses, 3 to 4 weeks apart, except that if the animal is less than 16 weeks of age, the final dose should be given no earlier than 16 weeks of age. The presence of maternal antibody is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals. Historically, annual revaccination with a single dose has been recommended for this product. The need for this booster has not been established.

For advice on revaccination frequency and annual booster vaccinations, consultation with a veterinarian is recommended.

Storage

Store in the dark at 2° to 8°C (35° to 46°F). Avoid freezing. Shake well. Use entire contents when first opened. Do not mix with other products, except as specified on the label. Inactivate all unused contents before disposal. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician.

● Non-Adjuvanted

Thimerosal, neomycin and polymyxin B added as preservatives.

ULTRA Hybrid FVRCP Caution

In the absence of a veterinarian-client-patient relationship, Federal law prohibits the relabeling, repackaging, resale, or redistribution of the individual contents of this package.

Patent Pending

ULTRA, Hybrid, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2017 Elanco US Inc. all rights reserved.

Elanco US Inc., Fort Dodge, Iowa 50501

Phone: 888-545-5973

VLN/PCN 196/16D7.20

25 Doses

25 Vials of Vaccine plus 25 x 0.5 mL Vials of Diluent

YL102092X

CPN: 1943030.2

ELANCO US INC.
FORT DODGE, IA, 50501
Customer Service:   317-276-1262
Technical Service:   800-428-4441
Website:   www.elanco.us
Email:   elanco@elanco.com
Every effort has been made to ensure the accuracy of the ULTRA Hybrid FVRCP information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2019 Animalytix LLC. Updated: 2019-09-30

Hide